09-12.00

里心

PTO/SB/21 (07-06

SEP 1 1 2005

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM Application Number 10/659,164 Filling Date September 10, 2003 First Named Inventor Eric Bacque et al. Art Unit 1626 Examiner Name Janet L. Coppins

Total Number of Pages in This Submission Attorney Docket Number 8674-000025 ENCLOSURES (check all that apply) After Allowance Communication to Fee Transmittal Form ☐ Drawing(s) Technology Center (TC) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Petition Appeal Communication to TC Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address | Terminal Disclaimer Other Enclosure(s) Extension of Time Request (please identify below): Return Receipt Postcard Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Remarks The Commissioner is hereby authorized to charge any additional Certified Copy of Priority fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Document(s) Account No. 08-0750. A duplicate copy of this sheet is enclosed. Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Reg. No. Attorney Name Firm Monte L. Falcoff 37,617 Harness, Dickey & Pierce, P.L.C. Jennifer Woodside Wojtala 50,721 Individual name Dennifer Koundords Kajirale Signature Date September 11, 2006

# CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature Date September 11, 2006	Typed or printed name	Monte L. Falcoff / Jennifer Woodside Wojtala	Express Ma:l Label No	EV 757 777 887 US (9/11/2006)
	Signature .4	Sellen to the book to forthe	Date	September 11, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





Application No.:

10/659,164

Filing Date:

September 10, 2003

Applicant:

Eric Bacque et al.

Group Art Unit:

1626

Examiner:

Janet L. Coppins

Title:

QUINOLYLPROPYLPIPERIDINE DERIVATIVES,

INTERMEDIATES AND COMPOSITIONS CONTAINING

THEM, AND PREPARATION THEREFOR

Attorney Docket:

8674-000025

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

# RESPONSE TO RESTRICTION AND ELECTION REQUIREMENT

Sir:

In response to the Office Action mailed August 9, 2006, please consider the following. In the above identified Office Action, the Examiner determined that currently pending Claims 1-24, are subject to a restriction requirement pursuant to 35 U.S.C. §121. The Examiner has required restriction to one of the following inventions –

 Claims 1-6 and 11, drawn to compounds of formula (I) and their compositions, classified in various subclasses of class 546;

- Claims 7-10, drawn to a process of preparing compounds according to formula (I), classified in class 546, various subclasses;
- III. Claims 12-14, drawn to compounds of different formula (II), classified in class 546, subclasses 152+;
- IV. Claims 15-17, drawn to compounds of formulae (A-C), classified in various subclasses of class 546;
- V. Claim 18, dawn to an intermediate compound of formula (VII), classified in class 546, subclasses 184+;
- VI. Claim 19, drawn to a different intermediate compound of formula (VIII), classified in class 546, subclass 152;
- VII. Claims 20-24, drawn to methods of using compounds according to formula (I), classified in various subclasses of class 514.

In addition, the Examiner has required an election of a single disclosed compound (in the specification), including an exact definition of each substituent on the base molecule (formulae I, II, A, B, or C), wherein a single member at each substituent group or moiety is selected.

### Response to Restriction Requirement

Applicants traverse the restriction requirement, as the examination of the above identified claims does not appear to impose a serious burden upon the Examiner. However, to facilitate prosecution, Applicants hereby elect to prosecute the claims of Group I corresponding to Claims 1-6 and 11.

The right is hereby reserved to file further continuation and/or divisional patent applications directed to the restricted subject matter and Applicants are not, in any manner, waiving or abandoning any rights to this subject matter.

The Office Action indicates that upon allowance of claims corresponding to Group I that commensurate claims corresponding to the withdrawn invention identified as Group VII may be rejoined in the application. Thus, Applicants reserve the right for rejoinder of Claims 20-24.

### Response to Election Requirement

In response to the election requirement, Applicants further elect the species for Formula I of Claim 1: 1-(2-Cyclohexylsulfanylethyl)-4-[3-(3-fluoro-6-methoxyquinolin-4-yl)-3-oxopropyl]piperidine-3-carboxylic acid, as identified in Claim 6 lines 24-26 and further at Page 5 lines 1-3 and Page 35 lines 25-27 of the specification, for example. With regard to Formula I of Claim 1, the elected species corresponds to the selection of the following moieties:  $R_1$  = fluorine;  $R_2$ = carboxyl group;  $R_3$  is a  $C_2$  substituted with a  $C_6$  cycloalkylthio, namely 2-cyclohexylsulfanylethyl, and  $R_4$  is a  $C_1$  alkyl or a methyl group. In this regard, Applicants submit that independent Claim 1, as well as dependent Claims 2-6 and 11 read upon the elected species.

## **CONCLUSION**

It is believed that a full and complete response has been made to the outstanding Office Action, and as such, the present application is in condition for allowance. Thus, prompt and favorable consideration of this Response is respectfully requested. If the

Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (248) 641-1600.

Respectfully submitted,

Dated: Suptember 11,2006

HARNESS, DICKEY & PIERCE, P.L.C. P.O. Box 828
Bloomfield Hills, Michigan 48303 (248) 641-1600

MLF/JMW

y: Ellissica

Monte L. Falcoff Reg. No. 37,617

Jennifer M. Woodside Wojtala Reg. No. 50,721